…as Kenya Manufactures ARVs
CATHERINE MUROMBEDZI
HEALTH CORRESPONDENT
The Global Fund (GF) to fight AIDS, Tuberculosis and Malaria has achieved a significant milestone by procuring first-line manufactured antiretroviral (ARVs) medicines for the first time. The quality-assured tenofovir, lamivudine, dolutegravir (TLD) anti HIV treatment, prequalified by the World Health Organisation, was sourced from a Kenyan pharmaceutical company and delivered to Mozambique. The stock is capable of treating over 72,000 people annually.
Notably, the Global Fund has been procuring some antimalarial medicines, insecticide-treated mosquito nets and essential medicines, such as co-trimoxazole, from Africa-based manufacturers, in line with its quality assurance requirements.

The Global Fund is working closely with partners to implement interventions that accelerate new health product introduction, support capacity building for regional manufacturing and procurement, and promote sustainable supply chains and capacity strengthening at global, national and community levels.
The initial regional manufacturing focus is to support capacity building in Africa, as this is where the biggest gap exists between high-volume demand and available supply of quality-assured health products.
Mark Edington, Head of Grant Management at the Global Fund said it was critical to accelerate the procurement and delivery of competitively priced quality medicines made in Africa.
“Accelerating and scaling up the procurement and delivery of competitively priced and quality African-made health products, including ARVs, across the continent will continue to be a top priority for the Global Fund,” said
Mark Edington.
“We look forward to deepening our collaboration with Africa’s rising health product manufacturing sector,” he added.

Strengthening Regional Capacity
This milestone highlights the Global Fund’s commitment to promoting regional manufacturing and capacity building in Africa. By partnering with organisations like Africa Centre for Diseases Control (CDC) and Unitaid, the Global Fund aims to:
Strengthen supply security
Expand access to quality-assured, affordable health products
Support sustainable supply chains.
Hui Yang, Head of Supply Operations at the Global Fund was happy with the expansion of quality assured and affordable medicines.
“This historic milestone highlights the Global Fund’s strong commitment to promoting regional manufacturing and capacity building. By fostering production based in Africa, we are strengthening supply security and expanding access to quality-assured, affordable health products across the continent, contributing to global health security,” said Hui Yang.

Prioritising African Health Product Manufacturing
The Global Fund will continue to prioritise procurement and delivery of competitively priced, quality African-made health products. This initiative supports Africa’s rising health product manufacturing sector and contributes to global health security.
Market Shaping Approach
The Global Fund’s NextGen approach focuses on accelerating new health product introduction, capacity building, and sustainable supply chains. Initial focus is on Africa, where demand for quality-assured health products exceeds available supply.
This achievement marks a significant step towards self-sufficiency in health product manufacturing in Africa, improving access to life-saving treatments for thousands of people.
Feedback: [email protected]

